Contents
Download PDF
pdf Download XML
90 Views
31 Downloads
Share this article
Research Article | Volume 30 Issue 12 (Dec, 2025) | Pages 222 - 228
To evaluate the usefulness of echocardiographic variables in predicting response of vasodilator therapy in patients of congenital heart disease patients with pulmonary arterial hypertension
 ,
 ,
 ,
 ,
1
MD, DM Assistant Professor Dept. Of Cardiology Shyam Shah Medical College Super Specialty Hospital, Rewa
2
MD, DM Professor Dept. of Cardiology G.B. Pant Postgraduate Medical Education and Research Center, New Delhi
3
MD, DM Assistant Professor Dept. of Cardiology G.B. Pant Postgraduate Medical Education and Research Center, New Delhi
Under a Creative Commons license
Open Access
Received
Nov. 26, 2025
Revised
Dec. 8, 2025
Accepted
Dec. 19, 2025
Published
Dec. 29, 2025
Abstract

Materials and Methods: The aim of the study is to evaluate the usefulness of echocardiographic variables in predicting response of vasodilator therapy in patients of congenital heart disease patients with pulmonary arterial hypertension. Detailed history, clinical examination was done and documented in detail to record the written parameters in proforma (Proforma attached). Basic hematological and biochemical workup (Hemogram, KFT, Serum electrolytes) was done upon admission. Results: We found significant positive correlation between PVRi with S/D ratio and tei Index with correlation coefficient of 0.553, 0.709 respectively at baseline. Significant negative correlation was seen between PVRiwith TAPSE,PAAT , FAC, RVOT VTI  with correlation coefficient of -0.844, -0.885, -0.663, -0.47 respectively. Non-significant moderate positive correlation was seen between PVRi with peak TRV , GLS, peak TRV /RVOT VTI  with correlation coefficient of 0.608, 0.399, 0.788 respectively. Non-significant mild negative correlation was seen between PVRi with TDI S' with correlation coefficient of -0.149. Conclusion: As echocardiography is non-invasive and widely used in routine clinical practice, measurement of these echocardiographic parameters could be of clinical utility for evaluating the disease severity of PAH in CHD patients and determining the changes in the patient’s hemodynamics. larger studies are needed to establish cut-off values and their sensitivity and specificity in predicting response to vasodilator therapy for each echocardiographic parameter. Also, our study adds to existing literature that supports evaluation of echocardiographic parameters in determining response to vasodilator therapy in CHD-PAH.

Keywords
INTRODUCTION

Pulmonary hypertension (PH) is a common complication of congenital heart disease (CHD) with increased blood flow[1]. This is especially a great disease burden for developing countries like India where medical access and hence diagnosis and treatment are delayed. Patients with easily repairable heart defects report at an older age with significant PH and now operability becomes a challenge[2].

PH is associated with adverse outcome following CHD surgery. Survival has improved due to with advancement in diagnostic and therapeutic strategy especially when treated with disease targeted pulmonary vasodilators[3].

One of the important dilemmas in the management of patients of congenital heart disease is the patients with borderline Pulmonary Vascular Resistance Index (PVRI) when PVRI is between 4 -8 WU.m2. If we operate them and the PVRI remains high postoperatively we are giving them a worser disease than they originally had. So, one wants to be sure that these patients have a significant element of reversibility before closing these defects[4]. The new strategy of treatment with pulmonary vasodilators like phosphodiesterase inhibitors, endothelin receptor antagonists prior to deciding about final closure of the defect has been described as Repair and Treat strategy. Many case reports suggest successful employment of this strategy in choosing patients with borderline PVRI for final repair. A repeat catheterization is needed to document significant fall in PVRI with treatment with pulmonary vasodilators. A variable duration of vasodilator therapy has been reported in various case reports[5].

Echocardiography is useful in initial assessment of severity of PAH and previous studies has shown correlation of echo variables with PVRI measurement. We propose that echocardiography can predict the response in PVRI while on vasodilator therapy and may be useful to time the cardiac catheterization needed for final confirmation. This study is aimed at studying how well echo parameters correlate with change in PVRI in follow up catheterization in patients with pulmonary hypertension planned for assessing response of pulmonary vasodilator therapy[6-7].

Echocardiography is important for timely assessment of disease progression in PAH-CHD, operability, follow-up and initiation and response to targeted PAH-pharmacotherapy in order to prevent PVD[8].

Echocardiographic markers of PH severity, such as the systolic-to-diastolic duration ratio of the tricuspid regurgitation jet or the right ventricular (RV) Tei index have been shown to be associated with hemodynamic measures obtained by cardiac catheterization and may predict long-term outcomes, including survival[9].

Traditionally, vasodilator testing is performed during cardiac catheterization, which is invasive and higher risk in pediatric patients with PH because of the need for sedation or anesthesia. Noninvasive bedside vasodilator testing may be an option to help guide therapy in selected patients.

MATERIALS AND METHODS

We enrolled total number of 18 patients with pulmonary hypertension due to congenital heart disease who was given vasodilator therapy. The study was conducted in the Department of Cardiology, GB Pant Hospital and MAMC, New Delhi.

 

INCLUSION CRITERIA:

  • Diagnosed patients of CHD-PAH undergoing cardiac catheterization with PVRi>4WU/m2 planned for vasodilator therapy.

 

EXCLUSION CRITERIA:

  • Patients with PVRi in operable range (<4WU/m2).
  • Complex congenital heart disease patients eg truncus arteriosus, single ventricle physiology.
  • Pre-tricuspid shunt lesion (ASD, PAPVC) with PAH.
  • Age <2 year

 

After selecting the patients based on inclusion and exclusion criteria, a baseline cardiac workup was done as per the Clinical Profile Proforma which includes:

  • Informed consent obtained from all patients according to the guidelines of our ethics committee (Consent and Assent form attached).
  • All patients underwent detailed trans thoracic echocardiography onPhilips EPIQ 7C fitted with a commercially available 5 MHz transducerbefore cardiac catheterization and after three-month course of vasodilator therapy (weight adjusted dose of Sildenafil, starting 0.5mg/kg going up to 4 mg/kg, in divided doses up to maximum dose 100 mg/day, Tadalafil (1 mg/kg body weight up to a maximum of 40 mg),Ambrisentan (5 mg/10 mg) depending on tolerability of the patient). Repeat echo was done within 48 hours of second cardiac catheterization. Detailed echo parameters including Size of the defect, chamber enlargement, Tricuspid regurgitation velocity, Pulmonary regurgitation velocity, PAAT, RVOT- VTI, TAPSE, RV- FAC, TDI-S’,Teiindex, RV-GLS Speckle Tracking echo was measured and correlated their improvement with catheterizationassessed parameters in response to vasodilators.

 

RESULTS

Table 1:- Demographic characteristics distribution.

Demographic characteristics

Frequency

Percentage

Age(years)

<=20 years

8

44.44%

>20 years

10

55.56%

Mean ± SD

22.17 ± 6.2

Median(25th-75th percentile)

21(17-25)

Range

15-34

Gender

Female

3

16.67%

Male

15

83.33%

Height(cm)

Mean ± SD

157.58 ± 14.77

Median(25th-75th percentile)

156.45(152-165.125)

Range

128-180.3

Weight(kg)

Mean ± SD

47.14 ± 10.83

Median(25th-75th percentile)

44.5(41.75-50)

Range

27-66.5

Body surface area(m²)

Mean ± SD

1.44 ± 0.19

Median(25th-75th percentile)

1.48(1.37-1.558)

Range

1.07-1.78

 

The study was conducted in the Department of Cardiology, GB Pant Hospital and MAMC, New Delhi. 18 diagnosed patients of CHD-PAH undergoing cardiac catheterization with PVRi>4WU/m2 planned for vasodilator therapy were included in the study. Echocardiographic variables and response of vasodilator therapy was assessed and results are as follows.

 

Table 2:- Descriptive statistics of cardiac catheterization parameters.

Cardiac catheterization parameters

Mean ± SD

Median(25th-75th percentile)

Range

Qp (L/min)

2.87 ± 2.17

2.12(1.85-2.728)

1.51-10.9

Qs (L/min)

3.08 ± 0.99

2.93(2.568-3.368)

1.7-6.25

Qp/Qs

0.98 ± 0.67

0.75(0.622-1.012)

0.24-2.81

PVR(woods unit)

36.59 ± 14.1

38.6(29.2-49.09)

6.86-52.4

SVR (woods unit)

31.1 ± 8.57

31.2(27.508-34.9)

13.6-52.4

PVRi(woods unit/m²)

52.77 ± 23.96

53.7(39.205-72.21)

12.21-89

SVRi(woods unit/m²)

43.89 ± 10.08

40.2(37.838-52.57)

30.5-65.5

PVR/SVR

1.18 ± 0.48

1.21(0.874-1.433)

0.32-2.1

 

All patients included in study had very high PVRi and PVR/SVR ratio suggestive of CHD with severe PAH. Mean value of PVRi (woods unit/m²) and PVR/SVR of study subjects was 52.77 ± 23.96 and 1.18 ± 0.48 respectively.

 

 

 

 

 

Table 3:- Descriptive statistics of echo parameters.

Echo parameters

Mean ± SD

Median(25th-75th percentile)

Range

LVEDV(mL)

116.78 ± 70.25

105(78-134.25)

66-375

LVESV(mL)

53.89 ± 23.45

51(38.575-64.625)

25-128

LVEF(%)

50.74 ± 10.83

51.85(47-55.1)

32-67

TAPSE(mm)

25.18 ± 7.93

24.25(22.25-28.5)

10-42

PeakPR  gradient

76.33 ± 17.4

81(69.25-86)

47-96

Diastolic PR gradient

48.17 ± 20.42

51(31-66.5)

23-68

RVEDV(mL)

81.03 ± 26.54

79.3(60.9-103)

35-132

RVESV(mL)

44.43 ± 12.49

44(38.225-55.7)

16.7-63

FAC

40.64 ± 11.69

38.7(29.3-50.55)

27.8-61

GLS(%)

-12.51 ± 2.82

-12.2(-14.4--9.65)

-18.1--9

 

Most of the patients included in study had normal TAPSE and FAC suggesting RV systolic function was normal in most of the patients. Mean TAPSE  was 25.18±7.93(mm) and Mean FAC was 40.64 ± 11.69 %.

 

Table 4:-Comparison of cardiac catheterization parameters between baseline and after vasodilator therapy.

Cardiac catheterization parameters

At baseline(n=18)

After vasodilator therapy (n=18)

P value

Mean RAP(mmHg)

Mean ± SD

7 ± 1.91

5.94 ± 2.73

0.106*

Median(25th-75th percentile)

7(6-7.75)

6(5-7.75)

Range

4-11

1-10

Mean PAP(mmHg)

Mean ± SD

94.22 ± 11.11

86.89 ± 12.23

<.0001*

Median(25th-75th percentile)

90(86.5-106.75)

86(75.5-99)

Range

80-110

70-107

Systolic PAP(mmHg)

Mean ± SD

126.83 ± 8.91

114.22 ± 11.77

0.001*

Median(25th-75th percentile)

128(121.75-133.75)

114(105.5-124.5)

Range

108-139

96-132

PVRi(woods unit/m²)

Mean ± SD

52.77 ± 23.96

38.98 ± 20.7

0.001*

Median(25th-75th percentile)

53.7(39.205-72.21)

38.57(20.115-49.2)

Range

12.21-89

8.72-84.64

PVR/SVR

Mean ± SD

1.18 ± 0.48

0.93 ± 0.4

0.001*

Median(25th-75th percentile)

1.21(0.874-1.433)

0.93(0.665-1.269)

Range

0.32-2.1

0.23-1.61

* Paired t test

Significant difference was seen in mean PAP (mmHg), systolic PAP (mmHg), PVRi(woods unit/m²), PVR/SVR between baseline and after vasodilator therapy.(p value <.05).

 

Mean ± SD of mean PAP (mmHg), systolic PAP(mmHg), PVRi(woods unit/m²), PVR/SVR at baseline was 94.22 ± 11.11, 126.83 ± 8.91, 52.77 ± 23.96, 1.18 ± 0.48 which was significantly higher as compared to after vasodilator therapy (86.89 ± 12.23 (p value<.0001), 114.22 ± 11.77(p value=0.001), 38.98 ± 20.7 (p value=0.001), 0.93 ± 0.4 (p value=0.001)).

 

This was suggestive of improvement in cardiac catheterization parameters in response to vasodilator therapy.

However, no significant difference was seen in mean RAP (mmHg) (p value=0.106) between baseline and after vasodilator therapy. Mean ± SD of mean RAP (mmHg) at baseline was 7 ± 1.91 and after vasodilator therapy was 5.94 ± 2.73 with no significant difference between them.

 

Table 5:-Correlation of Echo parameters with mean RAP, mean PAP, systolic PAP, PVRi and PVR/SVR at baseline:

Variables

Mean RAP(mmHg)

Mean PAP(mmHg)

Systolic PAP(mmHg)

PVRi(woods unit/m²)

PVR/SVR

Correlation coefficient

P value

Correlation coefficient

P value

Correlation coefficient

P value

Correlation coefficient

P value

Correlation coefficient

P value

TAPSE(mm)

-0.080

0.751

-0.538

0.021

-0.504

0.033

-0.844

<0.0001

-0.774

0.0002

Peak TRV (m/s)

-0.562

0.324

0.535

0.353

0.725

0.166

0.608

0.277

0.653

0.232

PAAT(msec)

-0.153

0.544

-0.691

0.002

-0.567

0.014

-0.885

<0.0001

-0.700

0.001

FAC (%)

-0.319

0.197

-0.664

0.003

-0.629

0.005

-0.663

0.003

-0.472

0.048

GLS(%)

0.247

0.324

0.089

0.725

0.124

0.624

0.399

0.101

0.385

0.115

S/D ratio

0.243

0.331

0.337

0.171

0.010

0.970

0.553

0.017

0.540

0.021

TDI S'(cm/s)

-0.317

0.200

-0.122

0.630

-0.193

0.444

-0.149

0.555

-0.257

0.303

Tei Index

0.141

0.576

0.607

0.008

0.503

0.033

0.709

0.001

0.478

0.045

RVOT VTI (cm)

0.394

0.106

-0.248

0.322

-0.176

0.485

-0.470

0.049

-0.436

0.070

Peak TRV (m/s)/RVOT VTI (cm)

0.392

0.515

0.755

0.140

0.726

0.165

0.788

0.114

0.744

0.150

Pearson correlation coefficient.

We found significant positive correlation between PVRi with S/D ratio and tei Index with correlation coefficient of 0.553, 0.709 respectively at baseline.

Significant negative correlation was seen between PVRiwith TAPSE,PAAT , FAC, RVOT VTI  with correlation coefficient of -0.844, -0.885, -0.663, -0.47 respectively. Non-significant moderate positive correlation was seen between PVRiwith peakTRV , GLS, peak TRV /RVOT VTI  with correlation coefficient of 0.608, 0.399, 0.788 respectively. Non-significant mild negative correlation was seen between PVRi with TDI S' with correlation coefficient of -0.149.

DISCUSSION

Echocardiography is a noninvasive and useful tool for diagnosing PAH, assessing disease severity, and determining response to treatment. Echocardiography-derived morphological and functional RV variables including RV-FAC, RV-TAPSE, and RV Tei-index may have potential for predicting the disease severity of PAH and determining response to treatment .It may become satisfactory substitutes for PVR measurement and for monitoring and follw-up of disease progression or response to PAH specific therapy[10].We aimed to identify echocardiography derived parameters for evaluating response to vasodilator therapy by correlating with hemodynamic parameters of cardiac catheterization  in the clinical course of CHD-PAH patients.

 

We enrolled 18 diagnosed patients of CHD-PAH with PVRi>4WU/m2 on cardiac catheterization planned for vasodilator therapy. We assessedEchocardiographic variables and their correlation with hemodyamic parameters obtained by catheterization in response to vasodilator therapy after 3 months of follow-up[11].

 

Mean age of our study subjects was 22.17 ± 6.2(years). Most of patients (83.33%) in our study were male.[12]

 

patients had VSD Eisenmenger and 4 patients had PDA

with Eisenmenger syndrome.

 

Mean value of hemoglobin of study subjects was 19.84 ± 3.33(gm%). Mean value of PVR (woods unit), SVR (woods unit), PVRi(woods unit/m²), SVRi(woods unit/m²) and PVR/SVR of study subjects at baseline was 2.87 ± 2.17, 3.08 ± 0.99, 0.98 ± 0.67, 36.59 ± 14.1, 31.1 ± 8.57, 52.77 ± 23.96, 43.89 ± 10.08 and 1.18 ± 0.48.

Out of 18 patients 12 (66.67%) cases were responders and 6 (33.33%) cases were non-responders to vasodilator therapy according to cut off value of 20% or more fall in PVRI or PVR/SVR ratio. 

 

There was significant reduction inPVRi,mean and systolic PAP, and PVR/SVR ratio from baseline in response to vasodilator therapy (p value <0.05).

Mean ± SD of mean PAP (mmHg), systolic PAP (mmHg), PVRi (woods unit/m²), PVR/SVR at baseline was 94.22 ± 11.11, 126.83 ± 8.91, 52.77 ± 23.96, 1.18 ± 0.48 which was significantly higher as compared to after vasodilator therapy (86.89 ± 12.23 (p value<.0001), 114.22 ± 11.77 (p value=0.001), 38.98 ± 20.7 (p value=0.001), 0.93 ± 0.4 (p value=0.001)) respectively[13].

 

There was significant positive correlation between PVRi (woods unit/m²) with S/D ratio and Tei Index at baseline with correlation coefficient of 0.553, 0.709 respectively.Tei Index and S/D ratio reflects systolic as well as diastolic function of RV. When PVRi fall there is decrease in Tei Index and S/D ratio which reflects improvement in systolic as well as diastolic function of RV in response to vasodilator therapy[14].

 

Similar results were found in study done by Y. Ogihara et al.[15] in 24 patients with PAH with respect to Tei index. After mean period of 13.3 ± 4.9 months follow up RV Tei index decreased from 0.55 ± 0.30 to 0.42 ± 0.17 and PVR decreased from 486 ± 380 dyne s cm-5 to 346 ± 252 dyne s cm-5. Also changes in RV Tei-index were correlated with the concomitant changes in PVR (r = 0.706, p = 0.002).

CONCLUSION

This was a prospective observational study to evaluate the usefulness of echocardiographic variables in evaluating response to vasodilator therapy in patients of congenital heart disease patients with pulmonary arterial hypertension (CHD-PAH).We enrolled 18 diagnosed patients of CHD-PAH with PVRi>4WU/m2 on cardiac catheterization and planned for vasodilator therapy. 14 patients had VSD Eisenmenger and 4 patients had PDA with Eisenmenger syndrome. Out of 18 patients 12 (66.67%) cases were responders and 6 (33.33%) cases were non-responders to vasodilator therapy according to cut off value of 20% or more fall in PVRI or PVR/SVR ratio. We found a significant reduction in PVRi from baseline in response to vasodilator therapy (52.77 ± 23.96 to 38.98 ± 20.7).There was significant improvement in RV-TAPSE (Increased 9.50±0.06 mm) and TDI S’ (increased by 1.82 ± 0.74 cm/s) from baseline in response to vasodilator therapy.

REFERENCES
  1. von 1.Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur. Respir. J. 2019 Jan 1;53(1).
  2. Simonneau G.; Montani D.; Celermajer D.S.; Denton C.P.; Gatzoulis M.A, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019, 53, 1801913.
  3. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J. Heart and Lung Transplant. 2019 Sep 1;38(9):879-901.
  4. Truong U.; Meinel K.; Haddad F.; Koestenberger M.; Carlsen J.; Ivy D, et al. Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. Cardiovasc. Diagn. Ther. 2020, 10, 1604–1624.
  5. Koestenberger M.; Apitz C.; Abdul-Khaliq H.; Hansmann G. Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016, 102, ii14–ii22.
  6. Koestenberger M.; Friedberg M.K. Non-Invasive Imaging for Congenital Heart Disease: Recent Innovations in Transthoracic Echocardiography. J. Clin. Exp. Cardiol. 2012, 1, 002.
  7. Singh D, Parikh GP, Butala BP. Anesthetic management of pediatric with congenital heart disease with pulmonary hypertension. Saudi Journal of Anaesthesia. 2014 Nov 1;8(5):127.
  8. Meinel K, Koestenberger M, Sallmon H, Hansmann G, Pieles GE. Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. Diagnostics. 2021 Jan;11(1):49.
  9. Siddiqui S, DiLorenzo MP, Krishnan U. Noninvasive Bedside Vasodilator Testing Using Echocardiography. CASE: Cardiovascular Imaging Case Reports. 2019 Jun;3(3):125.
  10. Rodriguez-Lopez J. Pulmonary hypertension in adult congenital heart disease. Curr Treat Options Cardiovasc Med. 2014; 16:328.
  11. Gurudevan SV, Malouf PJ, Kahn AM, Auger WR, Waltman TJ, Madani M, et al. Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. J. Am. Soc. Echocardiogr. 2007 Oct 1;20(10):1167-71.
  12. McCabe C, Vranesic II, Verdes MC, Kempny A, Khan U, Price L, et al. Right ventricular systolic to diastolic duration ratio: A novel predictor of outcome in adult idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 2019 Oct 15; 293:218-22.
  13. Alkon J, Humpl T, Manlhiot C, McCrindle BW, Reyes JT, Friedberg MK. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am. J. Cardiol. 2010 Aug 1;106(3):430-6.
  14. Dyer KL, Pauliks LB, Das B, Shandas R, Ivy D, Shaffer EM, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. 2006 J.Am. Soc. Echocardiogr. Jan 1;19(1):21-7.
  15. Ogihara Y, Yamada N, Dohi K, Matsuda A, Tsuji A, Ota S, et al. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension. J. Cardiol. 2014 Feb 1;63(2):149-53.

treatment in patients with pulmonary arterial hypertension. J. Cardiol.  2014 Feb 1;63(2):149-53.

Recommended Articles
Research Article
Evaluation of Microstructural Changes in Postencephalitic Patients with Memory Dysfunction Using Diffusion Tensor Imaging
Published: 28/06/2025
Download PDF
Read Article
Research Article
To study Lipid Profile Alterations in Young Adults with Sedentary Lifestyle
...
Published: 22/05/2025
Download PDF
Read Article
Research Article
Comparative assessment of coagulation factors in patients of mitral stenosis with inactive left atrial appendage in sinus rhythm versus atrial fibrillation
...
Published: 28/11/2025
Download PDF
Read Article
Research Article
Published: 27/10/2026
Download PDF
Read Article
Chat on WhatsApp
© Copyright Journal of Heart Valve Disease